SNCA and Parkinson disease: Increasingly, α-synuclein, a protein involved in synaptic plasticity and neurotransmission, is being explored as an additional CSF biomarker, and evidence may point to lower levels in Parkinson’s disease (PD) patients compared to controls [5], [7]–[9].